An Open Letter of Gratitude

By Bobby Gaspar, M.D., Ph.D.

On behalf of the whole team at Orchard, I would like to extend a humble thank you to all those that have participated in the MLD gene therapy clinical development program and to the broader MLD community who supported them throughout their journey.

The courage, commitment and resilience of the MLD community inspires us in our work every day. Orchard remains committed to MLD patients and families and will continue to work with a great sense of urgency, as we recognize the devasting impact this disease often has on families.

We also want to extend thanks to our partners at Fondazione Telethon and Ospedale San Raffaele, who have been instrumental in providing specialized care for some of the most complex and devastating health conditions.

We are excited about what the future may bring and the potential to open up new possibilities for people with rare inherited diseases.

You may also like…


Landmark Studies Shine A Light on the Need to Modernize the US Newborn Screening System

Recent publications in JAMA Network Open, Expert Evaluation of Strategies to Modernize Newborn Screening in the United States call for urgent change to ensure the U.S. newborn scre...


Rightsizing the U.S. Newborn Screening System

In the first 24 to 48 hours of a baby’s life, a small blood sample is taken to detect serious genetic conditions, some of them deadly, that can be treated if diagnosed early.1 Than...


Patient Engagement in the Era of Gene Therapy

The advent of potentially curative gene therapies – particularly for use in rare disease – is rapidly shifting society’s perspective on medicine, as well as the vital role that pat...

Title of the wysi

The site uses cookies to provide you with a more responsive and personalized service. By using this site, you agree to our use of cookies as set out in our cookie policy.

Please read our privacy policy and cookie policy for more information on the cookies we use and how to delete or block the use of cookies.